AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34809573
Drug: Perineural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perineural dexamethasone 8 mg with bupivacaine 0.25% 40 ml (Group TAPD)
Trial: 34809573
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% 40 ml (Group TAPA)
Trial: 32129681
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus rivaroxaban (2.5 mg b.i.d.)
Trial: 32129681
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg q.d.)
Trial: 32947455
Drug: Guided Exercise
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Exercise Therapy (GET)
Trial: 35116266
Drug: Extended field-IMRT
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended field-IMRT with concurrent cisplatin chemotherapy (40 mg/m2)
Trial: 35116266
Drug: Pelvic-IMRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic-IMRT with concurrent cisplatin chemotherapy (40 mg/m2)
Trial: 32843084
Drug: Fire needle
RxNorm normalized name: Fire Out
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fire needle control therapy
Trial: 33347022
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine for 8 weeks
Trial: 34826819
Drug: NSAIDs (parecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (parecoxib injection and subsequent loxoprofen tablets)
Trial: 32960662
Drug: postoperative radio‐chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: postoperative radio‐chemotherapy (p‐RTCT)
Trial: 33241466
Drug: 1.5% levofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% levofloxacin with 0.1% fluorometholone administered four times a day
Trial: 33241466
Drug: sixfold dilution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sixfold dilution of polyvinyl alcohol iodine (PAI) solution with 0.1% fluorometholone four times a day
Trial: 35121271
Drug: Face to
RxNorm normalized name: NAIR FACE TOP CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face to face (FtF) therapy
Trial: 35121271
Drug: Digital (dCBT-I)
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital (dCBT-I) therapy
Trial: 33303654
Drug: RAAS inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAAS inhibitors (RAASi)
Trial: 33023491
Drug: 0.04 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 mg/kg neostigmine
Trial: 33023491
Drug: 0.02 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg/kg neostigmine
Trial: 35700594
Drug: Taurine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurine (1.5 g)
Trial: 35700594
Drug: Placebo (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1.5 g of starch)
Trial: 35484039
Drug: MucoRice-CTB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MucoRice-CTB vaccine (6-g dose)
Trial: 33846198
Drug: standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care (SOC) with chemotherapy
Trial: 35532915
Drug: Compound intervention
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound intervention with digital scales, electronic pill bottles, and regret lottery incentives ($1.40 expected daily value)
Trial: 35532915
Drug: Compound intervention
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound intervention
Trial: 36352602
Drug: Yoga as
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga as a complementary treatment for epilepsy
Trial: 35271811
Drug: unilateral intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unilateral intravitreal AAV2(Y444,500,730F)‐P1ND4v2 injection (higher doses)
Trial: 35271811
Drug: unilateral intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unilateral intravitreal AAV2(Y444,500,730F)‐P1ND4v2 injection (lower doses)
Trial: 35271811
Drug: unilateral intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unilateral intravitreal AAV2(Y444,500,730F)‐P1ND4v2 injection
Trial: 34274079
Drug: Caffeine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (300 mg) given 45 minutes before training
Trial: 35799365
Drug: Capsaicin 8%
RxNorm normalized name: CAPSAICIN 8% PATCH KIT,4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin 8% Patch (C8P)
Trial: 35799365
Drug: Control low
RxNorm normalized name: Surestep Control Low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control low dose Capsaicin 0.025% patch (CON)
Trial: 36285763
Drug: Imported doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imported doses from Héma-Québec
Trial: 36285763
Drug: Transferred doses
RxNorm normalized name: SET,TRANSFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transferred doses between CBS regional distribution centers
Trial: 34101389
Drug: Three-weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three-weekly cisplatin 100 mg/m2
Trial: 35954612
Drug: Hedonic aroma
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hedonic aroma (essential oils) during chemotherapy (inhalation during T1, T2, T3)
Trial: 33619780
Drug: Calcipotriol 50
RxNorm normalized name: Calcipotriol 50 microgram/g cutaneous cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g cutaneous foam (Cal/BD foam)
Trial: 33177798
Drug: SPMC ½
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPMC ½ dose × 2
Trial: 33177798
Drug: SPMC 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPMC 1 dose × 2
Trial: 35607733
Drug: Sequential injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential injection of 1.5 mL of 0.5% hyperbaric bupivacaine with 15 μg of fentanyl followed by 1.5 mL of 0.5% isobaric bupivacaine (HIB group)
Trial: 35607733
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL of 0.5% hyperbaric bupivacaine mixed with 15 μg of fentanyl citrate (HB group)
Trial: 33307206
Drug: Yoga program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga program (12-week, 2x weekly/90-minute sessions)
Trial: 33307206
Drug: Education control
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education control group (1x weekly/60-minute lectures)
Trial: 35101266
Drug: Four-dose schedule
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-dose schedule (0–7–21–360)
Trial: 35101266
Drug: Three-dose schedule
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose schedule (days 0–30–360)
Trial: 35101266
Drug: Four-dose schedule
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-dose schedule (0–30–90–360)
Trial: 33414239
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg twice daily for 16 weeks
Trial: 33414239
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 16 weeks
Trial: 33414239
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg twice daily for 12 months
Trial: 33414239
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 12 months
Trial: 35361556
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity intervention (12-month duration, delivered twice weekly for the first 12 weeks, then once weekly; included cardiovascular, strength, balance, and flexibility exercises)
Trial: 34580251
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation (OAC) therapy
Trial: 36158133
Drug: Precision health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precision health education guidance after ESWL treatment
Trial: 32555026
Drug: High-Intensity Aerobic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Aerobic Interval Training (HIIT) in addition to treatment as usual (n = 13)
Trial: 32555026
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (n = 8)
Trial: 35216854
Drug: Routine prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine prescription education
Trial: 32842819
Drug: Endobronchial valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endobronchial valve therapy
Trial: 32726422
Drug: MVA‐BN‐RSV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA‐BN‐RSV vaccine (single dose)
Trial: 32726422
Drug: MVA‐BN‐RSV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA‐BN‐RSV vaccine (12-month booster dose)
Trial: 36278483
Drug: DEN-181 (medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEN-181 (medium dose)
Trial: 36278483
Drug: DEN-181 (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEN-181 (high dose)
Trial: 36278483
Drug: DEN-181 (low/medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEN-181 (low/medium doses)
Trial: 33905738
Drug: Medication reconciliation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reconciliation via a patient portal
Trial: 33905738
Drug: Medication reconciliation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reconciliation by a pharmacy technician (usual care)
Trial: 32505861
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + goserelin (C + G)
Trial: 32505861
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (C)
Trial: 32505861
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (C±G)
Trial: 32321353
Drug: Community treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community treatment as usual (Control)
Trial: 34697951
Drug: Distal approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal approach (DA) for local corticosteroid injection (LCI)
Trial: 34697951
Drug: Proximal approach
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proximal approach (PA) for local corticosteroid injection (LCI)
Trial: 33106117
Drug: Surgery, chemotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery, chemotherapy, and molecularly targeted agents (bevacizumab and PARP inhibitors)
Trial: 35044844
Drug: Intranasal orexin
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal orexin A (500 nmol)
Trial: 35044844
Drug: Intranasal orexin
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal orexin A
Trial: 32894278
Drug: Miltefosine and
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miltefosine and topical GM‐CSF (M + GM)
Trial: 35843520
Drug: Tralokinumab monotherapy
RxNorm normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tralokinumab monotherapy (ECZTRA 1 + 2)
Trial: 35403380
Drug: Azvudine and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azvudine and symptomatic treatment (FNC group)
Trial: 35403380
Drug: Standard antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiviral and symptomatic treatment (control group)
Trial: 32702878
Drug: Low-level light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level light therapy (LLLT) using a helmet-type device
Trial: 34313686
Drug: 7-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day antibiotic therapy (ciprofloxacin or trimethoprim/sulfamethoxazole)
Trial: 34313686
Drug: 14-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day antibiotic therapy (ciprofloxacin or trimethoprim/sulfamethoxazole)
Trial: 33157425
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg fast-release melatonin
Trial: 34487412
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg rifaximin 3 times/d plus 30-45 mL lactulose 3 times/d
Trial: 33567859
Drug: 1% high-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% high-molecular-weight hyaluronic acid (1 mL)
Trial: 33567859
Drug: 1% low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% low-molecular-weight hyaluronate (1 mL)
Trial: 32138344
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day oat beta-glucans
Trial: 35948382
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of prednisolone for 10 days
Trial: 35948382
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo treatment
Trial: 33971105
Drug: Neuropeptide Y
RxNorm normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuropeptide Y hormone in the ischemic phase
Trial: 35749352
Drug: Treatment cream
RxNorm normalized name: Acne Treatment Cream
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment cream (inert unscented lotion) administered by a provider
Trial: 34882581
Drug: Adjuvant vaccines
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant vaccines (given to all patients)
Trial: 35616047
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg methadone (MET)
Trial: 35616047
Drug: 7.5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg/kg dexmedetomidine (D7)
Trial: 35616047
Drug: 10 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg/kg dexmedetomidine (D10)
Trial: 35616047
Drug: 7.5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg/kg dexmedetomidine and 0.2 mg/kg methadone (DM7)
Trial: 35616047
Drug: 10 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg/kg dexmedetomidine and 0.2 mg/kg methadone (DM10)
Trial: 35616047
Drug: Low-dose dexmedetomidine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexmedetomidine (7.5 µg/kg)
Trial: 33681993
Drug: Rhinovirus A16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhinovirus A16 (3 different doses)
Trial: 33983765
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day pregabalin (EXP 1)
Trial: 33983765
Drug: 450 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg/day pregabalin (EXP 2)
Trial: 33860850
Drug: Probiotics (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (2 g for 30 days)
Trial: 33860850
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 g whey powder for 30 days)
Trial: 34372971
Drug: Trastuzumab maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab maintenance therapy
Trial: 34159386
Drug: Monthly smoking
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly smoking days for JHS girls
Trial: 35069955
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg (S group)
Trial: 32852294
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 150 µg epinephrine, 2 mL of 8.4% bicarbonate, and 100 µg fentanyl (LEBF)
Trial: 32472742
Drug: NEPA (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEPA (single oral dose)
Trial: 33857782
Drug: UVC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVC treatment
Trial: 33863564
Drug: 100μg selenium
RxNorm normalized name: SELENIUM 100MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100μg selenium tablet twice a day for 6 months
Trial: 33863564
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (100μg of starch) twice a day for 6 months
Trial: 35743485
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) treatment with a diode laser (810 nm, 6 J/cm2) for 6 weeks (1 session per week)
Trial: 35743485
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (simulated treatment)
Trial: 32744555
Drug: Phenolic compounds
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenolic compounds in skin and flesh of apples
Trial: 35861012
Drug: Be a
RxNorm normalized name: Tube Attaching Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Be a Mom, a self‐guided web‐based cognitive behavioral therapy intervention
Trial: 33528919
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention plus liraglutide 3.0 mg
Trial: 32374724
Drug: Integrated depression
RxNorm normalized name: Nerve depressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated depression screening and treatment program (Friendship Bench therapy and antidepressants)
Trial: 36763899
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) injections
Trial: 36034448
Drug: YPEG-rhGH 100
RxNorm normalized name: rhGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YPEG-rhGH 100 μg/kg/week
Trial: 36034448
Drug: YPEG-rhGH 120
RxNorm normalized name: rhGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YPEG-rhGH 120 μg/kg/week
Trial: 36034448
Drug: YPEG-rhGH 140
RxNorm normalized name: rhGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YPEG-rhGH 140 μg/kg/week
Trial: 36034448
Drug: Daily rhGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily rhGH 35 μg/kg/day
Trial: 36034448
Drug: YPEG-rhGH (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YPEG-rhGH (all doses)
Trial: 33099855
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane (ESP) block with 30 ml 0.25% bupivacaine at the T8 level
Trial: 33099855
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 50 mg of dexketoprofen trometamol (NSAID)
Trial: 32899959
Drug: PRP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP therapy
Trial: 33687145
Drug: Purple potato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purple potato extract rich in acylated anthocyanins (152 mg) and hydroxycinnamic acid conjugates (140 mg)
Trial: 616542428
Drug: Glycerol (G)
DrugBank: Glycerin (DB09462)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycerol (G)
Trial: 39287532
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg pro re nata
Trial: 32192496
Drug: LIG once
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LIG once weekly (QW)
Trial: 32192496
Drug: LIG twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIG twice weekly (BW)
Trial: 32192496
Drug: Enrofloxacin and
RxNorm normalized name: ENROFLOXACIN 5 mg in 1 mL / SILVER SULFADIAZINE 10 mg in 1 mL AURICULAR (OTIC) EMULSION [Enrofloxacin and Silver Sulfadiazine Otic Emulsion]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrofloxacin and silver sulfadiazine twice daily (C)
Trial: 35951253
Drug: 1-hour training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour training in stimulant diversion prevention
Trial: 32029903
Drug: Naltrexone (NTX)
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone (NTX) treatment for at least three months
Trial: 35012827
Drug: BTA injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTA injections into the subjacent orbicularis oris muscle (4 points group)
Trial: 35012827
Drug: BTA injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTA injections into the bilateral nasolabial fold region (6 points group)